• Amit Mitra, Shweta Bansal, Wei Wang, Sandor Falk, Einath Zolty, and Robert W Schrier.
• University of Colorado Health Sciences Center, 4200 East 9th Ave. Box C-281, Denver, CO 80262, USA.
• Nephrol. Dial. Transplant. 2007 Aug 1; 22 (8): 2349-53.

BackgroundSepsis has a high mortality (50-80%) when associated with acute renal failure (ARF). Oxidant injury and proinflammatory cytokines and chemokines have been shown to increase with endotoxaemia-related ARF. Since erythropoietin (EPO) has been demonstrated to possess anti-oxidant and anti-inflammatory properties, EPO may have therapeutic efficacy for treating ARF associated with endotoxaemia.MethodsWild-type mice were given 2.5 mg/kg of intraperitoneal (i.p.) endotoxin, lipopolysaccharide (LPS), and studied 16 h later. Thirty minutes prior to LPS, the mice were given either EPO or vehicle.ResultsDuring endotoxaemia, EPO was found to significantly attenuate the renal dysfunction, as assessed by glomerular filtration rate (48.1 +/- 12.4 microl/min vs 136.7 +/- 30.2, P < 0.05). Renal blood flow and mean arterial pressure were not significantly different between the two groups. The renal dysfunction during endotoxaemia was associated with a decrease in renal superoxide dismutase (SOD). The EPO-related renal protection was associated with reversal of the effects of endotoxin on renal SOD.ConclusionThis is the first demonstration of a renal protective effect of EPO on endotoxin-related renal dysfunction.

25 keywords...

hide…